On Wednesday, Oct. 21, 2020, Blue Matter Consulting and Greater Zurich Area co-hosted a virtual panel discussion for a select group of leaders from biopharma companies interested in establishing or expanding their operations in Europe. The panel addressed—at a high level—the key decisions that biopharmaceutical companies must make when considering a move into Europe. These include:
- Whether to enter European markets
- If entering, which “pathways” to take (e.g., Licensing, Partnering, or “Going-It-Alone”)
- How to design and staff European operations
The event consisted of informal presentations by two European biopharma leaders and a Q&A session. This document provides a summary of the session.
